Premium
The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats
Author(s) -
Baldan Helen M.,
De Rosa Helene J.,
Brunetti Iguatemy L.,
Ximenes Valdecir F.,
Machado Rosângela G. P.
Publication year - 2007
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.570
Subject(s) - pyrazinamide , rifampicin , pharmacokinetics , isoniazid , pharmacology , volume of distribution , chemistry , drug interaction , distribution (mathematics) , area under the curve , tuberculosis , medicine , antibiotics , biochemistry , mathematical analysis , mathematics , pathology
Abstract Tuberculosis chemotherapy involves combination of the drugs isoniazid (INH), rifampicin (RMP) and pyrazinamide (PYR) for a 6‐month period. The present work investigated the influence of RMP and PYR on the pharmacokinetic parameters of INH when groups of rats were pre‐treated for 21 days with INH alone or in combination with RMP and/or PYR, in the following amounts per kg body weight: INH 100 mg; INH 100 mg+RMP 100 mg; INH 100 mg+PYR 350 mg; INH 100 mg+PYR 350 mg+RMP 100 mg. It was found that the co‐administration of PYR caused an increase in the INH distribution volume ( V d / F ), half‐life of elimination ( t 1/2β ) and clearance ( Cl T / F ), and a decrease in the area under curve 0 to 24 h ( AUC ). Co‐administration of RMP caused an increase in the Cl T / F and a decrease in the AUC . The combination INH+PYR+RMP caused an increase in the Cl T / F and a decrease in the AUC . These significant pharmacokinetic interactions between the tuberculostatic drugs might be related to differences in the therapeutic and toxic effects. Copyright © 2007 John Wiley & Sons, Ltd.